Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer

N/ACitations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

For palliation of patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC), the major classes of commonly used cytotoxic chemotherapeutic agents are platinum agents (cisplatin, carboplatin), taxanes (paclitaxel, docetaxel), and antimetabolic agents (methotrexate, 5-fluorouracil). Cetuximab, a monoclonal antibody directed against the extracellular domain of the epidermal growth factor receptor, also shows modest activity against R/M HNSCC. Because the overall management of patients with R/M HNSCC often involves multidisciplinary input, this review focuses on data that help guide decision-making in scenarios in which palliative chemotherapy is planned. Avenues for ongoing research are also presented. © JNCCN-Journal of the National Comprehensive Cancer Network.

Cite

CITATION STYLE

APA

Fury, M. G., & Pfister, D. G. (2011, June 1). Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. JNCCN Journal of the National Comprehensive Cancer Network. Harborside Press. https://doi.org/10.6004/jnccn.2011.0056

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free